{"id":"cyclobenzaprine-er-amrix","safety":{"commonSideEffects":[{"rate":"29","effect":"Drowsiness"},{"rate":"11","effect":"Dizziness"},{"rate":"21","effect":"Dry mouth"},{"rate":"6","effect":"Fatigue"},{"rate":"5","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclobenzaprine works primarily through central nervous system depression, acting on the brainstem to reduce muscle tone and spasticity. It is structurally related to tricyclic antidepressants and may work through noradrenergic pathways. The extended-release (ER) formulation allows for once-daily dosing with sustained therapeutic levels.","oneSentence":"Cyclobenzaprine is a centrally acting muscle relaxant that reduces muscle tension by depressing activity in the brainstem.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:32:17.646Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Muscle spasm associated with acute musculoskeletal conditions"},{"name":"Muscle spasticity in chronic conditions"}]},"trialDetails":[{"nctId":"NCT01041495","phase":"PHASE4","title":"Cyclobenzaprine Extended Release (ER) for Fibromyalgia","status":"TERMINATED","sponsor":"State University of New York - Upstate Medical University","startDate":"2009-06","conditions":"Fibromyalgia, Pain, Sleep","enrollment":37},{"nctId":"NCT03443960","phase":"PHASE1","title":"Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2018-01-29","conditions":"Healthy Subjects","enrollment":60},{"nctId":"NCT01028014","phase":"NA","title":"Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2010-04","conditions":"Urethral Sphincter Activity","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AMRIX"],"phase":"marketed","status":"active","brandName":"cyclobenzaprine ER (AMRIX)","genericName":"cyclobenzaprine ER (AMRIX)","companyName":"State University of New York - Upstate Medical University","companyId":"state-university-of-new-york-upstate-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclobenzaprine is a centrally acting muscle relaxant that reduces muscle tension by depressing activity in the brainstem. Used for Muscle spasm associated with acute musculoskeletal conditions, Muscle spasticity in chronic conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}